fda glp-1 compounding crackdown news october 2025 on off-brand Ozempic products set to take effect, threatening supply and access for many FDA steps up crackdown on

Of the individuals from the SGLT2i cohort, 87% were from the USA and 13% were from the UK-EU

In a motion to dismiss the lawsuit last year, lawyers for Mochi Health called the complaint part of a nationwide campaign to bolster Lillys profits by dictating patient care through the elimination of compounded drugs as a treatment option for weight management. The lawsuit is ongoing

Clinical eligibility for GLP-1 drugs was determined using BMI and the following comorbidities as specified in NHIS: coronary heart disease, prior stroke, prior heart attack, angina, high blood pressure, and high cholesterol

Phentermine raises heart rate and blood pressure, which stacks with the modest HR increase from GLP-1s

Disclosures: Jessica Sosio: Nothing to Disclose, Karla Geisse: Nothing to Disclose, Lindsey Valdiviez: Nothing to Disclose, Roudi Bachar: Nothing to Disclose, Adrian Singson: Nothing to Disclose, Oluwagbenga Serrano: MERCK: Stock - publicly traded company 2229 ALFAPUMP SYSTEM IN REFRACTORY ASCITES: RESULTS FROM THE POSEIDON STUDY AT 24 MONTHS Hugo Vargas 1 Deepika Devuni 2 Mangesh Pagadala 3 Angela Cheung 4 Sumeet Asrani 5 Gijs Klarenbeek 6 Jeroen Capel 6 Jasmohan Bajaj 7 K Rajender Reddy 8 Patrick Kamath 9 Florence Wong 10 , 1 Mayo Clinic Arizona, 2 University of Massachusetts, 3 Methodist Transplant Center, Dallas, 4 The Ottawa Hospital, 5 Liver Consultants of Texas, 6 Sequana Medical, 7 Virginia Commonwealth University, 8 University of Pennsylvania, 9 Mayo Clinic Rochester, 10 University of Toronto Background: The standard of care for refractory ascites (RA) in cirrhosis is repeated large volume paracentesis (LVP)